Core Viewpoint - The company is expanding its product sales network globally, particularly in Europe, America, and Asia, with a focus on its new product series and NAD+ products [1] Group 1: Product Development and Sales - The new product series from the subsidiary RIAGEV is set to cover major global markets including Europe, America, and Asia [1] - Sales of related products are expected to increase steadily in Europe, America, and Asia by 2025 [1] Group 2: Strategic Focus - The company will continue to enhance its investment in synthetic biology applications within the life sciences sector [1] - There is an ongoing effort to extend the industrial chain, enrich the product structure, and enhance brand value [1] - The goal is to build a more competitive synthetic biology business segment [1]

诚志股份（000990.SZ）1月29日在投资者互动平台表示，美国BLS子公司RIAGEV新产品系列以及 NAD+产品的销售网络覆盖欧洲、美洲、亚洲等全球主要国家和地区。2025年，相关产品的推广工作顺 利，在欧美以及亚洲的销售额持续增加。在生命医疗领域，公司将持续加强合成生物领域应用研究的投 入，不断延伸产业链条，丰富产品结构，提升品牌价值，构建更具综合竞争实力的合成生物业务板块。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：贵公司子公司美国 BLS 公司相关产品应用开发方面处 于国际领先地位， 拥有全球范围内的销售网络，请问是否销售网络涉及欧盟成员国？ ...